Arcellx, Inc.

NasdaqGS:ACLX Stock Report

Market Cap: US$6.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Arcellx Management

Management criteria checks 3/4

Arcellx's CEO is Rami Elghandour, appointed in Jan 2021, has a tenure of 5.25 years. total yearly compensation is $18.18M, comprised of 4% salary and 96% bonuses, including company stock and options. directly owns 1.18% of the company’s shares, worth $79.69M. The average tenure of the management team and the board of directors is 4.5 years and 4.8 years respectively.

Key information

Rami Elghandour

Chief executive officer

US$18.2m

Total compensation

CEO salary percentage3.96%
CEO tenure5.3yrs
CEO ownership1.2%
Management average tenure4.5yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Seeking Alpha • Dec 17

Arcellx: Funded Into 2028 With Strong Clinical Data

Summary Arcellx (ACLX) is positioned to disrupt multiple myeloma cell therapy with anito-cel, leveraging superior efficacy, safety, and scalable manufacturing. ACLX's $576 million cash runway extends into 2028, mitigating dilution risk and supporting its transition to commercialization post-2026 launch. Anito-cel's 96% ORR, 74% CR/sCR, and clean safety profile differentiate it from competitors, especially against Carvykti’s neurotoxicity concerns. The Kite partnership ensures rapid 17-day turnaround and broad distribution, enhancing ACLX's commercial leverage in a $12B+ market. Read the full article on Seeking Alpha
Analysis Article • Aug 10

Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results

NasdaqGS:ACLX 1 Year Share Price vs Fair Value Explore Arcellx's Fair Values from the Community and select yours As you...
Analysis Article • Jul 11

We're Not Very Worried About Arcellx's (NASDAQ:ACLX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Mar 17

Arcellx Impressive Safety Data Leaves Doubts

Summary Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story. Hold rating based on the uncertainty of upcoming potential approval. Read the full article on Seeking Alpha
Seeking Alpha • Jan 16

Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy

Summary Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma, with a 97% response rate and low neurotoxicity, potentially differentiating it in a crowded market. Financially robust, ACLX has cash reserves to fund operations into 2027, supported by a collaboration with Gilead's Kite subsidiary. Despite the promising data, the myeloma treatment landscape is competitive, and ACLX must overcome significant hurdles in cost, manufacturing, and delivery. Given the current $3.5 billion market cap, I maintain a "Hold" sentiment, anticipating a pullback for a more favorable entry point, although your risk tolerance may vary. Read the full article on Seeking Alpha
Seeking Alpha • Sep 10

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Summary Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows strong clinical results in relapsed/refractory multiple myeloma, even for high-risk patients. Arcellx’s strategic partnership with Kite Pharma validates its technology, potentially leading to milestone payments of up to $935 million. Anito-cel’s Phase 3 trial results are expected by yearend 2024, with a possible BLA submission in 2025, entering a $34.4 billion market. Despite a premium valuation, ACLX's strong pipeline, promising clinical data and strategic partnership with Gilead's Kite justify a "strong-buy" rating. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Rami Elghandour's remuneration changed compared to Arcellx's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$18mUS$721k

-US$229m

Sep 30 2025n/an/a

-US$218m

Jun 30 2025n/an/a

-US$188m

Mar 31 2025n/an/a

-US$162m

Dec 31 2024US$21mUS$653k

-US$107m

Sep 30 2024n/an/a

-US$40m

Jun 30 2024n/an/a

-US$54m

Mar 31 2024n/an/a

-US$51m

Dec 31 2023US$25mUS$601k

-US$71m

Sep 30 2023n/an/a

-US$130m

Jun 30 2023n/an/a

-US$183m

Mar 31 2023n/an/a

-US$190m

Dec 31 2022US$14mUS$565k

-US$189m

Sep 30 2022n/an/a

-US$170m

Jun 30 2022n/an/a

-US$95m

Mar 31 2022n/an/a

-US$80m

Dec 31 2021US$23mUS$470k

-US$65m

Compensation vs Market: Rami's total compensation ($USD18.18M) is above average for companies of similar size in the US market ($USD8.44M).

Compensation vs Earnings: Rami's compensation has been consistent with company performance over the past year.

CEO

Rami Elghandour (46 yo)

5.3yrs
Tenure
US$18,183,311
Compensation

Mr. Rami Elghandour serves as President, Chief Executive Officer and Chairman of the Board of Directors at Arcellx, Inc. since January 2021. Mr. Elghandour joined the Arcellx, Inc. on January 22, 2021. Pre...

Leadership Team

NamePositionTenureCompensationOwnership
Rami Elghandour
Chairman of the Board5.3yrsUS$18.18m1.18%
$ 79.7m
Michelle Gilson
Chief Financial Officer3.9yrsUS$7.04m0.12%
$ 8.3m
Christopher Heery
Chief Medical Officer5yrsUS$4.77m0.040%
$ 2.7m
Aileen Fernandes
Chief Operating Officer1.3yrsno datano data
Narinderjeet Singh
Chief Technical Officer4.5yrsno datano data
Heba Nowyhed
Chief Scientific Officer2.3yrsno datano data
Myesha Lacy
Chief Investor & Communications Officer5.3yrsno datano data
Maryam Abdul-Kareem
General Counsel & Chief Legal Officer3.8yrsno datano data
Kate Aiken
Chief People Officer5.3yrsno datano data
Neeraj Teotia
Chief Commercial Officer5yrsUS$2.00mno data
Helen Kim
VP & Head of Regulatory Affairs1.3yrsno datano data
4.5yrs
Average Tenure
46yo
Average Age

Experienced Management: ACLX's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rami Elghandour
Chairman of the Board5.3yrsUS$18.18m1.18%
$ 79.7m
Andrew Galligan
Independent Director1.1yrsUS$978.96k0.0085%
$ 575.2k
David Lubner
Independent Director5.7yrsUS$498.39k0.037%
$ 2.5m
Kristin Myers
Independent Director1.1yrsUS$975.02kno data
Jill Carroll
Independent Director8.6yrsUS$491.21k0%
$ 0
Olivia Ware
Independent Director3.9yrsUS$477.28k0%
$ 0
Kavita Patel
Independent Director4.3yrsUS$479.46kno data
Ali Behbahani
Independent Director11.3yrsUS$491.53k0.0079%
$ 532.7k
4.8yrs
Average Tenure
50.5yo
Average Age

Experienced Board: ACLX's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/30 13:28
End of Day Share Price 2026/04/27 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arcellx, Inc. is covered by 10 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Geoffrey MeachamCitigroup Inc
Cory KasimovEvercore ISI